share_log

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga ·  Apr 30 20:06

Gainers

  • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million.
  • GeneDx Hldgs (NASDAQ:WGS) shares rose 43.54% to $15.79. The company's market cap stands at $411.3 million. As per the news, the Q1 earnings report came out yesterday.
  • BioRestorative Therapies (NASDAQ:BRTX) shares moved upwards by 16.93% to $1.45. The company's market cap stands at $9.8 million.
  • Vaccinex (NASDAQ:VCNX) shares moved upwards by 15.72% to $6.77. The company's market cap stands at $10.7 million.
  • Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 14.19% to $8.61. The market value of their outstanding shares is at $9.2 million.
  • Tenet Healthcare (NYSE:THC) stock increased by 9.93% to $109.0. The company's market cap stands at $10.8 billion. The company's, Q1 earnings came out today.

Losers

  • SHL Telemedicine (NASDAQ:SHLT) stock decreased by 10.0% to $5.0 during Tuesday's pre-market session. The company's market cap stands at $81.9 million.
  • Nektar Therapeutics (NASDAQ:NKTR) stock declined by 8.87% to $1.33. The market value of their outstanding shares is at $244.3 million.
  • GlucoTrack (NASDAQ:GCTK) shares fell 8.17% to $0.51. The market value of their outstanding shares is at $13.7 million.
  • GE HealthCare Techs (NASDAQ:GEHC) shares declined by 7.81% to $82.0. The market value of their outstanding shares is at $37.4 billion. As per the news, the Q1 earnings report came out today.
  • Virios Therapeutics (NASDAQ:VIRI) stock fell 7.28% to $0.44. The market value of their outstanding shares is at $8.3 million.
  • 180 Life Sciences (NASDAQ:ATNF) shares decreased by 7.15% to $1.82. The market value of their outstanding shares is at $1.5 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment